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ENGLISH SUMMARY 
Tablets and smartphones are increasingly often being used to support workflows of 
healthcare professionals in clinical settings. Studies have shown that mobile devices 
can facilitate workflows by providing access to clinical information systems while 
supporting the mobility requirements of the users. The use of tablets is promising as 
they provide a reasonable screen size while remaining easily portable. Studies have 
primarily reported on the effects on workflow by using tablets in patient wards. There 
is an interest in the use of tablets in clinical microbiology, where they can potentially 
be used to facilitate workflows of advanced diagnostic tests to provide accurate and 
timely results.  
In recent years, many advanced molecular diagnostic tests have become available for 
use in clinical microbiology. The tests can provide earlier identification of pathogens 
infecting the bloodstreams that often leads to sepsis. Sepsis is associated with high 
mortality, but early identification of the causative microorganisms allows for a 
targeted antimicrobial treatment of sepsis patients that can improve the outcome. A 
disadvantage of the advanced molecular diagnostic tests is that they often have 
workflows that are more complex than the routine diagnostic methods.  
This PhD thesis is part of a research project that aims to develop a rapid molecular 
diagnostic test called MuxBCT, which is used for the identification of microorganisms 
from positive blood cultures (BCs). The objective of this PhD thesis was to investigate 
how to design and evaluate a MuxBCT tablet app that aims to facilitate the MuxBCT 
diagnostic test.  
Four studies were conducted as a part of this PhD thesis. The first study was an 
observational study of the workflow of medical laboratory scientists (MLSs) during 
BC analysis, which provided a set of requirements that the MuxBCT app needed to 
support. Based on the findings from the first study, a prototype of MuxBCT was 
designed. In study two, four usability experts and four MLSs evaluated the prototype 
in a participatory heuristic evaluation, which revealed domain-related usability issues. 
The results of study two guided the further design of the MuxBCT app and led to an 
optimization of the user interface and changed the app functionality. 
In study three, the MuxBCT app design and system architecture was evaluated 
through a clinical simulation. Four MLSs used the MuxBCT app in a clinical 
microbiology laboratory to guide the use of a simulated MuxBCT test for 
identification of eight microorganisms from mocked BCs. The study findings 
indicated that the system design was feasible for supporting the MuxBCT test as all 
eight microorganisms were correctly identified. Study four was a non-interventional 
study, where the MuxBCT app was used together with a prototype of the MuxBCT 
test. Four MLSs analyzed positive BCs in a clinical microbiology laboratory in 
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parallel with routine diagnostics. For 124 BCs, the MuxBCT results had an accuracy 
of 92.7% and were available near the time of preliminary routine test results. 
Additionally, the users reported that the app had successfully facilitated the use of the 
MuxBCT test.  
In conclusion, this PhD thesis demonstrates that specialized tablet apps can be used 
to support the workflows of advanced diagnostic tests in clinical laboratories.  
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DANSK RESUME 
Tablets og smartphones bliver i stigende grad anvendt til at understøtte arbejdsgange 
af sundhedsprofessionelle i kliniske miljøer. Studier har vist, at de mobile enheder kan 
facilitere arbejdsgange ved at give adgang til kliniske informationssystemer imens 
brugerens behov for mobilitet understøttes. Brugen af tablets er lovende, da de 
tilbyder en rimelig skærm størrelse imens de er nemt flytbare. Studier har primært 
rapporteret effekten af tablets på arbejdsgange i patientafsnit.  Der er en interesse i 
brugen af tablets i klinisk mikrobiologi, hvor de kan bruges til at facilitere 
arbejdsgange relateret til avancerede diagnostiske tests for at opnå præcise og rettidige 
resultater.  
Igennem de seneste år er mange avancerede molekylære diagnostiske tests blevet 
tilgængelige til brug i klinisk mikrobiologi. Testene kan på kortere tid identificere 
mikroorganismer, der inficerer blodbanerne og som ofte leder til sepsis. Sepsis er 
forbundet med en høj dødelighed, men en tidlig identifikation af de forårsagende 
mikroorganismer tillader en målrettet antibakteriel behandling, der kan forbedre 
udfaldet af behandling. En ulempe ved de avancerede molekylære diagnostiske tests 
er, at de generelt medfører arbejdsgange som er mere komplekse end de 
rutinemæssige diagnostiske metoder.    
Denne ph.d.-afhandling er en del af et forskningsprojekt, hvor fokus har været 
udviklingen af en hurtig molekylær diagnostisk test kaldet MuxBCT, der bruges til 
identifikation af mikroorganismer fra positive bloddyrkninger. Målet for denne ph.d.-
afhandling var at designe og evaluere en MuxBCT tablet app, der har som mål at 
facilitere brugen af den diagnostiske MuxBCT test. 
Fire studier blev udført som en del af denne ph.d.-afhandling. Det første studie var et 
observationsstudie af bioanalytikeres arbejdsgang ved analyse af bloddyrkninger, 
hvilket udmundende i nogle basale krav, der skulle understøttes af MuxBCT appen. 
Baseret på fundene fra studiet blev en prototype af MuxBCT designet. I studie to blev 
prototypen analyseret af fire usability eksperter og fire bioanalytikere igennem en 
participatorisk heuristisk evaluering, der viste domæne-relaterede usabilityproblemer. 
Resultaterne af studie to guidede det videre design af MuxBCT appen og førte til en 
optimeret brugergrænseflade og ændringer i appens funktionalitet.  
I studie tre blev design og systemarkitektur af MuxBCT appen evalueret igennem et 
klinisk simulationsstudie. Fire bioanalytikere anvendte MuxBCT appen i et klinisk 
mikrobiologisk laboratorium til at guide brugen af en simuleret MuxBCT test til at 
identificere otte mikroorganismer fra kunstige bloddyrkninger.  Studiets resultater 
indikerede, at det med systemdesignet var muligt at understøttede MuxBCT testen, da 
alle otte mikroorganismer blev identificeret korrekt. Studie fire var et ikke-
interventionsstudie, hvor MuxBCT appen blev brugt sammen med en prototype af 
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MuxBCT testen. Fire bioanalytikere analyserede i alt 124 positive bloddyrkninger i et 
klinisk mikrobiologisk laboratorium, hvilket foregik i parallel med den rutinemæssige 
diagnostik. MuxBCT resultaterne havde en nøjagtighed på 92,7% og var tilgængeligt 
nær tidspunktet for det rutinemæssige præliminære testresultat.  Ydermere 
rapporterede brugerne at MuxBCT appen med succes havde faciliteret brugen af 
MuxBCT testen.  
Som konklusion har denne ph.d.-afhandling vist at specialiserede tablet apps kan 
anvendes til at understøtte arbejdsgange af avancerede diagnostiske tests i kliniske 
laboratorier.  
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PREFACE 
This PhD thesis has been submitted for assessment in partial fulfillment of the PhD 
degree at the Department of Health Science and Technology, Aalborg University, 
Denmark. This thesis presents the work I conducted during my PhD study in the 
period March 2013 to March 2016. The work of this PhD study was done under the 
supervision of Ole Hejlesen and Louise Pape-Haugaard, Aalborg University.  
The PhD study was carried out as a part of the Multiplex Blood Culture Test 
(MuxBCT) project. The project was supported by a grant from the Danish National 
Advanced Technology Foundation (now Innovation Fund Denmark). The other 
partners in the project were:  
 AdvanDx, Inc. 
 Department of Clinical Microbiology, Aalborg University Hospital  
 DTU Nanotech 
 DTU Systems Biology 
This thesis is based on four studies that were conducted during the PhD study. Five 
papers were prepared from the results of the four studies, which are presented in 
Chapter 7. Two papers were accepted and presented at conferences, one paper has 
been published in a journal, and two papers have been submitted to journals. Some of 
the material in this thesis is a part of these papers.  
The descriptions of MuxBCT diagnostic test in this thesis are based on a prototype of 
the test, which was used in the final study that is a part of this thesis. The MuxBCT 
test is likely to undergo further changes in its development, and future versions of the 
test may deviate from the descriptions in this thesis.  
Throughout this thesis, the term tablet will refer to a tablet computer. The term app 
will refer to an application, i.e., a software application designed for use on tablets 
and/or smartphones.  
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CHAPTER 1. INTRODUCTION 
Handheld mobile computers such as tablets and smartphones have in recent years 
become ubiquitous in daily life, and the devices are being introduced in clinical 
settings [1–5]. Mobility is an important aspect of many workflows in clinical settings, 
and the use of these modern mobile devices has the potential for supporting access to 
patient information while providing the mobility required by the users [2,6]. 
However, there is a need for more research to optimize the use of smartphones and 
tablets as a part of the clinical workflow [2,7].  
Informatics have an important role in clinical microbiology as the laboratory 
information systems (LIS) is continuously used throughout many diagnostic 
workflows [8].  The integration of informatics in clinical microbiology is considered 
important to provide timely and accurate results of microbiological testing [8]. Some 
diagnostic test instruments have the ability to communicate data directly with the 
LIS, which facilitates the operator’s workflow by reducing hands-on time, and by 
reducing errors related to manual entry of results [8,9].  
In the past decade advances in molecular diagnostic tests for use in clinical 
microbiology has provided an opportunity for earlier identification of the 
microorganism causative of bloodstream infection (BSI). BSIs often lead to sepsis, 
which is associated with a high risk of mortality. While commercial molecular 
diagnostic tests are available, they have not replaced the common diagnostic tools 
[10–12]. Studies have shown that the molecular tests reduce time to administration 
of an effective antimicrobial therapy, which can improve patient outcome [12]. 
However, the use of molecular diagnostic tests often requires a more complex 
workflow in comparison to the use of routine diagnostic methods [11,13,14].  
This thesis is based on studies conducted as part of a research project called the 
MuxBCT project. The focus of the MuxBCT project is the research, development, 
and evaluation of a new molecular diagnostic test called MuxBCT. The MuxBCT test 
is a fluorescence in situ hybridization (FISH) molecular diagnostic test. The test aims 
to provide direct identification of 18 microorganisms at a species or group level from 
positive blood cultures (BCs) within an hour.  
Tablets and smartphones present an opportunity to support the complex diagnostic 
workflows that take place in clinical laboratories through the development of 
specialized apps. Tablets provide a reasonable compromise between screen size user 
mobility. A tablet app may be able to facilitate the workflow of advanced diagnostic 
test such as MuxBCT by providing context-based test guidance and by offering the 
means of integration with the LIS to promote efficient communication of test results.   
DESIGN AND EVALUATION OF A TABLET APP FOR SUPPORTING THE CLINICAL MICROBIOLOGY DIAGNOSTIC 
TEST MUXBCT 
16 
CHAPTER 2. BACKGROUND 
This chapter introduces the background for the thesis. It aims to provide a description 
of sepsis, the importance of a timely initiated effective treatment, and how advanced 
molecular diagnostic tests are available for providing an early identification of the 
causative pathogens. The background also describes the growing use of tablets in 
clinical workflows, the benefits that may be gained by use of tablets in clinical 
settings, the importance of usability of such systems, and how the usability can be 
evaluated during the design and development of the systems.   
2.1. SEPSIS 
Sepsis is a severe inflammatory response to an infection in which the body causes 
damage to its tissue and organs [11,15]. The underlying pathogens that are causative 
of sepsis can be bacteria, yeasts, viruses or parasites [16]. Most available data on the 
epidemiology of sepsis is from developed countries [17]. However, sepsis is 
considered a global burden and a major challenge in medicine as the estimated 
incidence of severe sepsis is 18-20 million cases each year  [11,16,18]. It is estimated, 
that sepsis is the cause of death for up to 5.3 million people annually [18]. The 
treatment of sepsis patients is associated with large expenses [19]. Infants, the elderly, 
and those with weakened immune systems or chronic diseases are at an increased risk 
of being affected [19,20]. 
Sepsis is categorized by degree of severity as sepsis, severe sepsis or septic shock. 
The mortality of sepsis increases with the severity with a mortality of around 13-17% 
for sepsis, 20-30% for severe sepsis, and up to 50% for septic shock [16,18,19,21–
24]. The severity can progress rapidly if proper treatment is not administered [23]. 
Each hour of delay in the initiation of an effective antimicrobial therapy leads to an 
increase in mortality [25].  
In the US, 2% of all hospitalized patients are estimated to have sepsis of which half 
require intensive care treatment [26]. However, half of all sepsis patients in the need 
of intensive care are never transferred to an intensive care unit [23]. Those who 
initially survive sepsis have a high mortality in the years following hospital discharge 
[27]. Additionally, the quality of life is often reduced due to physical and cognitive 
decline [27,28].   
2.1.1. TREATMENT 
The treatment of sepsis relies on an early recognition and the initiation of treatment 
bundles. International guidelines recommend that once a patient is diagnosed with 
sepsis, an antimicrobial therapy must be initiated quickly [25]. The initial therapy 
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typically covers a broad spectrum to be effective against all likely pathogens. The 
choice of antibiotics is a complex decision, which can depend on individual patient 
factors such as underlying disease, known infections, and general antibiotic 
susceptibility of pathogens that are prevalent in the community of the patient and the 
hospital [25].  
For 9-27% of sepsis patients the initially administered antimicrobial therapy is not 
appropriate [29–32]. If the initial antimicrobial therapy is inadequate, i.e. a therapy 
not effective against the causative pathogen, it is associated with an increased patient 
mortality [29–31]. For patients with septic shock every hour of delay before an 
effective treatment is started after the onset of hypotension, the mortality of the septic 
shock patient rises by nearly 8% [22]. Septic shock patients who initially receive an 
inadequate therapy has a fivefold increase in mortality [29].  
Identification of the underlying causative pathogen and its susceptibility is necessary 
to guide the treatment of a sepsis patient. When results become available from 
microbiological testing, the initial antimicrobial therapy can be changed if the 
treatment is found ineffective or it can be deescalated to an antibiotic with a narrow-
spectrum [25].  
BCs are considered the gold standard for the identification of microorganisms 
causative of bacteremia [33]. Once a patient is diagnosed with sepsis, sets of two or 
three BCs are collected before initiation of antimicrobial therapy to avoid sterilization 
of the samples. The BCs contain media that is optimized for the growth of either 
aerobic or anaerobic microorganisms. The BCs are drawn from different locations, 
which may include vascular devices such as catheters [25]. Once the BCs have been 
collected, they are transported to a clinical microbiology laboratory, where the BCs 
are incubated.  
BCs typically require a microorganism growth time of 6 to 48 hours before they are 
signaled as positive by the automated incubator system [34,35]. Although BCs are 
considered the gold standard, their use is not optimal due the delay in pathogen 
identification caused by microorganism growth time. An additional issue is that 30-
40% of BCs are negative for patients with sepsis [16,21].   
Once BCs are signaled as positive, they are routinely examined by Gram stain and 
wet mount microscopy [36]. This provides a preliminary result about the pathogen’s 
Gram stain reaction, morphology, and motility. The Gram stain is a quick test to 
conduct, and studies have shown that Gram stains have a very high accuracy [36,37]. 
The timely availability of Gram stain results is critical, as the Gram stain reaction can 
guide optimizations of the patient’s treatment. The communication of the Gram stain 
results has shown to have a greater impact on antimicrobial therapy changes than the 
communication of antibiotic susceptibility results [38]. Delays in the availability of 
Gram stain results have shown to lead to an increased patient mortality [39]. After 
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the availability of Gram stain results 30-45% of patients have their initial 
antimicrobial therapy adjusted [36]. The preliminary results are followed by a 
subculture of microorganisms on plate media, which requires grows overnight before 
the causative pathogen can be identified [10]. Antibiotic susceptibility testing 
requires additional time before availability. 
2.1.2. MOLECULAR DIAGNOSTIC TESTS 
Treatment of sepsis requires diagnostic tests that can rapidly provide specific 
identification of pathogens and potentially provide information on antibiotic 
susceptibility [40,41]. The sepsis diagnostic tests should ideally be simple to use, and 
they should support quick communication of results to the attending staff of the sepsis 
patient. To support result communication, the test should ideally be integrated into 
existing clinical information systems (CISs) such as the LIS [40]. The development 
of rapid diagnostic tests and their integration into the clinical microbiology laboratory 
use is expected to lead to an improved outcome for sepsis patients and a reduction in 
the associated treatment costs [40]. This section will introduce molecular diagnostic 
tests for sepsis, and then provide further information on peptide nucleic acid (PNA) 
FISH molecular diagnostic tests. 
During the last decade, many rapid molecular diagnostic tests based on different 
technologies have become commercially available for use in rapid pathogen 
identification for sepsis patients, and their potential benefits over routine methods 
have generated a substantial interest [10,12,33,40,42–45]. The rapid tests have the 
ability to reduce identification time of pathogens from positive BCs to hours instead 
of days. This allows for selection of an antimicrobial therapy based on the hospital’s 
empiric antibiogram for the identified pathogens before susceptibility testing results 
are available [46].  
There are general disadvantages to the molecular diagnostic tests as they have grown 
more complex to operate [13,14,40]. Additionally, their results may be difficult to 
interpret and requires the assistance of an expert (e.g. a clinical microbiologist or an 
infectious disease physician) [40]. Furthermore, many of the molecular tests are labor 
intensive and require manual processing steps for analysis preparation, which can 
introduce workload issues and increases the risks of errors during processing (e.g. 
sample contamination) [41].  
QuickFISH and PNA-FISH (AdvanDx, Inc., Woburn, MA, USA) are two 
commercially available FISH-based rapid diagnostic tests that are are used for 
identification of microorganisms from positive BCs. The tests function by containing 
PNA probes with fluorescent markers that bind to specific rRNA sequences of a 
target microorganism. The targeted microorganisms can then be identified by 
fluorescence microscopy. There are several variants of QuickFISH and PNA-FISH, 
which each target two or three different microorganisms at a species or group level 
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(e.g. Staphylococcus aureus or coagulase-negative staphylococci). The QuickFISH 
tests can provide results within 1 hour while the PNA-FISH tests require 2-3 hours. 
Studies of QuickFISH tests have shown an accuracy of 98-99% when compared with 
routine diagnostic methods [47–49]. A limitation of these tests is that they do not 
provide information on antimicrobial resistance thus further testing is still required. 
The tests are not integrated into automated instruments and, therefore, require manual 
processing and interpretation. Results obtained from the tests are initially noted on 
paper forms and then digitized at a workstation. When used together with an 
antimicrobial stewardship team (AST) the tests can provide an earlier optimized 
treatment, which has been shown that their use can lead to a reduced length of stay, 
reduced mortality, and lower treatment costs [50,51].  
The use of rapid molecular diagnostic tests has the potential to improve patient 
treatment by providing the information necessary to begin an effective antimicrobial 
therapy. However, if the rapid diagnostic tests are not effectively implemented into 
the diagnostic workflow, their benefits may be lost [52]. The results obtained from 
the tests require quick communication from the clinical microbiology laboratory to 
the patient’s attending staff to ensure an effect of the antimicrobial therapy [44,52]. 
The use of an AST can assist in ensuring an efficient communication of results and 
provide the expertise needed to optimize patient treatment based on the rapid 
diagnostic test results. This may lead to improved patient survival, decreased length 
of stay in the hospital, and decreased treatment costs [35,46,53]. This is supported by 
a recent review by Buehler et al., which suggests that the implementation of rapid 
molecular diagnostic tests combined with direct communication of results may 
provide an earlier optimization of the antimicrobial therapy and thus improve patient 
outcome [42]. 
2.1.3. TEST TURNAROUND TIME 
A quick turnaround time (TAT) for sepsis diagnostic tests is essential to provide a 
timely effective antimicrobial therapy for sepsis patients. Together with the accuracy 
of test results the TAT is considered the important aspects of test results by physicians 
[54].  If test results are delivered too late, they may not be able to have an impact on 
the antimicrobial therapy of a patient.  
There are many different challenges in optimizing the TAT of diagnostic tests that 
aim to detect the causative pathogens of a BSI based on positive BCs. Once a BC has 
been drawn, four main phases affect microbiological testing TAT for the BC as 
shown in Figure 1. 
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Figure 1. Four main phases of the diagnostic processing of BC analysis once a sample has 
been drawn, which combined make up the TAT for microbiological testing of a BC. 
The introduction of rapid molecular tests into routines procedures will likely reduce 
the time for a final identification of a microorganism (i.e. the time for analysis of the 
positive BC). However, it will not affect the other phases of the BC diagnostic 
process, e.g., sample transportation time and result communication time. To make an 
efficient diagnostic workflow and improve the TAT, it is not enough to introduce 
rapid diagnostic tests, but the entire diagnostic process should be considered [55].   
Transportation time from drawing of BCs until incubation plays a role in the TAT, 
but may also influence BC positivity. Samples collected at hospitals without local 
clinical microbiology departments may require transportation to a centralized 
laboratory. Additionally, samples that are collected during night shifts may take 
longer to be brought to the laboratory. Akan et al. demonstrated that delays for more 
than 24 hours until initiation of BC incubation leads to an increase in BC negativity, 
which may require more samples to be collected [56].  
The incubation time of BCs until they are signaled for positive growth varies, but for 
many microorganisms a typical growth time is 6-48 hours [34]. Clinical microbiology 
laboratories are often not staffed for 24 hours daily. If a BC is signaled positive for 
growth outside working hours of the laboratory, it will be analyzed the next morning. 
If BCs are drawn outside the operating hours of the laboratory, they risk being stored 
for a period before incubation is started. Such delays in BC incubation may negatively 
influence the time to detection of growth. A study by Kerremans et al. showed that 
the use of an intermediate BC incubator accessible outside laboratory’s working 
hours can lead to a median reduction of 10 hours in the time to detection of 
microorganism growth [57]. Some molecular diagnostic tests can operate directly on 
whole blood, which can eliminate the incubation time [45,58]. 
Positive BC analysis results are considered critical values, which means there is a 
high priority on communicating them from the clinical microbiology laboratory to 
the patient’s attending staff [59]. The communication of results relies primarily on 
phone calls. A commonly reported challenge in the communication of critical values 
is to communicate them directly to the patient's attending physician [60]. Automatic 
notification systems have shown potential to reduce communication time and 
decrease the risk of communication errors [61,62]. While automated communication 
is promising it can be difficult to implement as many clinical microbiologists prefer 
to communicate preliminary BC results over the telephone to ensure that the results 
are interpreted correctly [54].  
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Batching of diagnostic tests to optimize workflow and reduce costs is a common 
occurrence in clinical microbiology laboratories when processing BCs with routine 
methods or molecular tests [35,63]. The unloading of positive BCs may be done at 
specified times throughout the day instead of immediately when the BCs are signaled 
as positive. If the laboratory does not operate during the night, then there may also 
be a large amount of positive BCs for processing in the morning.  
To summarize, many factors influence the TAT of diagnostic processing of a BC. 
Some of these factors can be improved by the introduction of rapid diagnostic tests. 
However, a focus on optimizing the entire workflow will likely bring improvements 
to patient outcome [64]. Informatics play a large role in the diagnostic workflow in 
clinical microbiology, and efficient use of informatics tools has shown to improve 
the workflow leading to improved testing both accuracy and timeliness [8]. The 
integration of diagnostic test instruments can reduce the hands-on time for operators 
and reduce a need for double documentation [8,9]. Furthermore, integration of rapid 
diagnostic tests with the LIS may provide the foundations for a more efficient 
communication of results [40]. 
2.2. TABLETS IN CLINICAL SETTINGS 
Clinical workflows in healthcare are generally complex and often requires that staff 
move around to different locations, e.g., patient wards, diagnostic departments, and 
laboratories [6,65,66]. Access to CISs plays a major role in many of aspects of the 
workflows, e.g., to access patient information and document work. Mobile computing 
devices in the form of personal digital assistants (PDAs), smartphones, and tablets 
are tools that can potentially help meet the needs for access to patient-related 
information of healthcare workers while allowing them to remain mobile. The 
potential benefits of mobile access to CISs as part of a workflow in hospitals have 
been of interest to researchers for over a decade [66]. The ability to access clinical 
information and lookup guidelines at the point of care has the potential to improve 
workflows, which may lead to better informed clinical decisions and thereby 
improved patient care [67,68].  
Early research on the use of mobile computing devices to support workflow in 
healthcare has mainly been based on the use of PDAs [66,69]. Studies demonstrated 
the potential benefits by providing users with mobile access to information and by 
supporting mobile documentation. However, the impact on clinical workflow has not 
been clear [69]. With the use of mobile devices, data can be captured directly at the 
point-of-care, which may lead to a reduction of errors due to the elimination of double 
documentation (e.g. initially making notes of results on paper forms that are 
digitalized later) [67]. Workflow benefits by the use of PDAs were demonstrated for 
workflows where timeliness and rapid communication was important [69]. This 
indicates that mobile devices may be useful for supporting the workflows of rapid 
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sepsis diagnostic tests, where timeliness and rapid communication are essential 
elements. 
Studies have also revealed issues that were encountered with the use of PDAs in 
health care settings. The usability of these mobile devices can be a major barrier to 
their use in clinical workflows [67]. Potential usability issues are data security, 
physical dimensions of the device, the weight of the device, poor battery, poor 
display, challenging data entry, unstable connectivity, poor integration with other 
CISs, and negative perception of the devices by patients [66,67].  
The development of modern mobile devices such as smartphones and tablets are 
promising for use in clinical settings, as they may bring the benefits observed with 
PDAs while having fewer barriers preventing their use. An advantage offered by 
smartphones and tablets over PDAs is that many users are already familiar with the 
devices from their personal use. Additionally, these devices generally have long 
battery life and strong connectivity support as they often support both Wi-Fi and 
cellular networks. Tablets are especially interesting as a tool to introduce for use in 
healthcare, as they provide a large screen size while still being easily portable [5]. 
Tablets and smartphones are a promising tool for supporting the integration of rapid 
diagnostic microbiological tests and have been predicted to play an increasingly 
significant role in clinical microbiology to support rapid diagnostic tests [70]. Thus, 
these mobile devices may play a major role in optimizing and supporting the 
workflow of rapid diagnostic tests in clinical microbiology with an end goal of 
prodiving accurate and timely results.  
2.2.1. CLINICAL WORKFLOW 
Smartphones and tablets have in recent years become a daily used tool for many 
people, and it is only natural that their use has spread to clinical settings [2,3,7]. Most 
of the existing knowledge about the utilization of these mobile computing devices 
and their potential effects on workflow are based on studies of PDAs [7,69,71].  
Healthcare professionals have an interest in the use of tablets in clinical settings as it 
may facilitate their workflow, e.g., through point-of-care access to Electronic Health 
Records (EHRs) [3,7,72,73]. Similarly, for use related to clinical microbiology, there 
are many apps available that offers guidance for antimicrobial stewardship by 
providing information on drugs and diseases, which can assist the process of selecting 
an optimal antimicrobial therapy [74,75]. 
A study in 2013 provided 115 internal medicine residents with a tablet for use in their 
work [72]. The study revealed that at the end of the study 84% of the residents were 
positive towards the utilization of the tablet. The use of tablets in clinical settings is 
by many physicians perceived as useful for their workflow. A survey conducted in 
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2013 with responses from almost 3,000 US physicians revealed that 40% used tablets 
and about 20% utilized the tablets in clinical settings [3]. Access to drug information 
and access to the EHR was reported as a primary use of the tablets.  
A study by Crowson et al. examined the use of tablets connected to the EHR for 
facilitation of resident workflow in a head and neck surgery department [76]. The 
tablets used in the study supported lookup of patient data and allowed for entry of 
notes into the EHR from the tablet. The study results revealed a significant time 
saving of 50% for patient rounds when tablets were used compared to use of paper. 
Additionally, 80% of the residents reported an improvement in morale when the 
tablets were used, and 70% indicated that they felt the tablets allowed them to spend 
more time with patients. Similarly, a study by Fleischmann et al. demonstrated that 
the use of tablets could facilitate the workflow of physicians during ward rounds [4]. 
A study by Horng et al. showed that physicians using tablets in an emergency 
department could decrease time spent at workstations and increase time spent at 
bedside [77].  
While the recent studies on the use of tablets suggest a potential for facilitating 
clinical workflows in patient wards, there is a lack of published scientific literature 
describing the use of tablets in clinical laboratories. 
2.2.2. TABLET USABILITY 
While the potential advantages of using tablets to provide mobile access to CISs is 
promising, there are also usability challenges that must be overcome to make 
efficient use of the devices. These challenges include ensuring ease of use, data 
security, data privacy, integration of the mobile computing devices into common 
workflow routines, and acceptance by end users. This section will describe usability 
evaluation methods used for identifying usability barriers in the development cycle 
of both stationary and mobile CISs.  
A definition of usability is provided by the ISO 9241-11 standard as: “the extent to 
which a product can be used by specified users to achieve specified goals with 
effectiveness, efficiency and satisfaction in a specified context of use.” [78]. From 
this definition of usability, it is important to notice that usability not only depends 
on its ability to help users achieve their goals but that a system’s usability is also 
dependent on the context of use. This is an important consideration for the 
development of apps for clinical use, which will be used as tools to support 
workflows that will generally be complex. Furthermore, the context of use is 
drastically different between patient wards and laboratories, which should be 
considered during app design and development.   
The introduction of a new CIS can have a large effect on the clinical workflow, and 
may have unintended consequences if the developed system’s usability is poor and 
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it does not match the requirements of the users in their clinical workflows [79,80]. 
An example of this is a handheld prescription system with usability issues, which   
can introduce errors during data retrieval or data entry that can potentially lead to 
patient harm [81]. If the end users feel that the system complicates their clinical 
workflow, there is also a risk of clinical workarounds being introduced, which may 
lead to errors [79].  The implementation of a new CISs will often result in 
organizational changes, which should be planned to increase the likelihood of a 
successful system implementation [82].  The involvement of end users during the 
system development phase can also be essential to ensure that the system meets the 
requirements of the users.  
Usability evaluations are critical in the development of CISs to identify system 
design flaws that can be improved thus leading to an optimization of the system’s 
usability [83]. Usability evaluation methods can rely on experts, end users (i.e. 
domain experts), or a combination of both. For CISs examples of commonly used 
usability evaluation methods are heuristic evaluation, clinical walkthrough, and 
think aloud [83]. The different usability evaluation methods each have their 
strengths and weaknesses, but may complement each other and be used in various 
parts of the development cycle of the CISs [83,84]. In heuristic evaluation, experts 
inspect a systems user interface against guidelines to identify potential issues [85]. 
It is a rapid and cheap method to conduct that can be used at several stages 
throughout system development.   
When dealing with complex clinical workflows, usability evaluation experts will 
often not be able to discover usability issues that relate to the workflow of the end 
user [83]. The introduction of end users into teams conducting the usability experts 
can lead to insights about domain-related usability issues. An example of this is 
participatory heuristic evaluation, in which domain experts are briefly trained in the 
heuristic evaluation [86]. A study demonstrated that there was an interest amongst 
clinicians to participate in the participatory heuristic evaluation and that it could 
lead to the discovery of domain specific issues [87].  
In recent years, there has been a growing interest in clinical simulation studies for 
the evaluation of CISs in near-live settings [88–90].  Clinical simulation can be 
used to uncover usability issues and estimate the effect of a CIS before system 
implementation [89,90]. Clinical simulation studies require a high fidelity prototype 
of the system being evaluated to provide realistic results about the use of the CIS in 
clinical workflows [91]. 
Pilot studies with implementations of near fully developed systems can be evaluated 
by combining several different usability evaluation methods, for example by 
collecting notes on system use, observing study participants, and by interviewing 
participants [84]. Additionally, errors that occur during pilot studies can be examined 
closely to potentially identify underlying usability issues. In evaluation studies, the 
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system usability scale (SUS) questionnaire can be used for a quick estimation of a 
system’s usability that also allows for comparison against the usability of other 
systems or previous versions of the system being evaluated [92]. The SUS 
questionnaire contains ten statements that are answered on a Likert scale. The SUS 
questionnaire has previously been used for evaluation of a clinical tablet app [93].  
2.3. BACKGROUND SUMMARY 
BSIs can lead to sepsis, which is associated with high patient mortality. For every 
hour of delay in the initialization of an effective antimicrobial therapy leads there is 
an increased risk of mortality for sepsis patients. Due to the urgency of starting 
treatment, the initial antimicrobial therapy is commonly based on empirical data and 
targets a broad spectrum of microorganisms. For about 20% of patients with severe 
sepsis or septic shock, the initially administered antimicrobial therapy is not effective.  
BCs are the gold standard for identification of microorganisms in the bloodstream 
and typically require an incubation period that spans from 6-48 hours. Preliminary 
results in the form of Gram stain results are available shortly after the BC is signaled 
positive for growth of microorganisms from an automated incubator system. 30-45% 
of sepsis patients have their initial antimicrobial therapy readjusted after the 
availability of preliminary results (i.e. Gram stain results). Final identification and 
antimicrobial susceptibility results typically requires one or more days before 
availability.   
The recent developments in rapid molecular diagnostic tests for use in clinical 
microbiology provides a potential for obtaining final identification of pathogens from 
positive BCs in a shorter timeframe than routine methods. An earlier identification 
of pathogens can allow for a faster optimization of a patient antimicrobial therapy, 
which will lead to an improved outcome for many patients. However, the molecular 
diagnostic methods are generally more complex in use than routine methods, which 
is a barrier to their widespread use.  
The use of tablets has spread to clinical settings, and recently studies have shown that 
they have the potential to facilitate complex workflows of healthcare professionals. 
Clinical microbiology laboratories are heavily dependent on CISs during most 
workflow routines, which means that there is a growing interest in the use of tablets 
and dedicated apps for supporting the workflow of diagnostic tests in clinical 
microbiology. The tablets may be able to facilitate workflows of rapid molecular 
diagnostic tests thereby reducing the TAT and promoting a high accuracy of test 
results.  However, there is a lack of published literature describing how such tablets 
may affect the workflow in clinical laboratories, and how specialized tablet apps 
should be designed to promote successful use amongst end users.  
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CHAPTER 3. MUXBCT MOLECULAR 
DIAGNOSTIC TEST 
This PhD thesis is a part of a larger research project, where the ongoing focus is the 
development of the rapid molecular diagnostic test MuxBCT, which will be described 
in this chapter. The MuxBCT test is still being developed and optimized, but this 
chapter describes a fully functional prototype of the MuxBCT test. Further references 
to the MuxBCT test throughout this thesis will refer to the test as described in this 
chapter unless otherwise specified.   
The MuxBCT test aims to provide microorganism identification results in less than 
an hour for 18 groups or species of microorganisms commonly encountered in 
positive BCs. The MuxBCT test is based on FISH and can be considered a new 
generation diagnostic test that builds upon the QuickFISH tests. The major difference 
between MuxBCT and QuickFISH is a much larger coverage of microorganisms in 
one test by the MuxBCT test. However, the increased coverage of microorganisms 
has also added complexity to the test, which must be successfully handled to ensure 
that accurate microorganism identification results are obtained.   
3.1. TEST DESIGN 
The MuxBCT tests consists of a slide that is divided into 10 reaction wells, which is 
shown as a rendering in Figure 2. Positive BC material is mixed with MuxBCT 
reagents, which is then transferred to the reaction wells. The slide is heated for 
approximately 17 minutes to fixate and hybridize the sample before it is read with 
fluorescence microscopy in a dark room. One of the reaction wells acts a sample 
classifier of the BC being examined and determines which of the other wells need to 
be examined. Each of the nine other reaction wells allows for identification of two 
different bacteria or yeasts at a species or group level (e.g. coagulase-negative 
staphylococci). When the microorganisms bind to PNA probes in the reaction wells, 
a fluorescent green or red signal is observable through fluorescence microscopy. This 
allows for positive identification of the microorganisms targeted in each well as 
shown in Figure 3.  
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Figure 2. Rendering of the MuxBCT slide. The slide contains 10 reaction wells (smaller 
circles), which each provide molecular identification of two to three microorganisms at a 
species or group level. 
 
 
Figure 3. Example of prototype MuxBCT test reaction well read by fluorescence microscopy 
positive for: A) Enterococcus faecalis; B) Enterococcus faecium.  
Each positive finding in the classification well requires that three additional wells be 
examined. Additionally, one well is used as a negative control well based on findings 
in the classifier well. In rare cases where the classifier indicates findings of all 
covered microorganism categories, i.e., Gram-positive, Gram-negative bacteria, and 
yeasts, the MuxBCT test is not usable due to the lack of a control well. When 
analyzing monomicrobial BCs, which is the most prevalent scenario, a user will 
examine five reaction wells in total.  An overview of the ten reaction wells of 
MuxBCT is provided in Table 1. 
DESIGN AND EVALUATION OF A TABLET APP FOR SUPPORTING THE CLINICAL MICROBIOLOGY DIAGNOSTIC 
TEST MUXBCT 
28 
Table 1. MuxBCT reaction wells and microorganism coverage based on the fluorescent signal.   
Reaction well Green positive Red positive 
1. Gram-positive 
bacteria 
Staphylococcus aureus Coagulase-negative 
staphylococci 
2. Gram-positive 
bacteria 
Enterococcus faecalis Enterococcus faecium 
3. Gram-positive 
bacteria 
Streptococcus agalactiae Streptococcus pneumoniae 
4. Yeasts Candida glabrata Candida tropicalis 
5.  Classifier — — 
6. Yeasts Candida albicans Candida krusei 
7. Yeasts Cryptococcus 
neoformans/gattii 
Candida parapsilosis 
8. Gram-negative 
bacteria 
Pseudomonas aeruginosa Acinetobacter (genus) 
9. Gram-negative 
bacteria 
Stenotrophomonas 
maltophilia 
Enterobacteriaceae (family) 
10. Gram-negative 
bacteria 
Escherichia coli Klebsiella pneumoniae 
 
3.2. TEST INTERPRETATION 
For MuxBCT to provide results with accurate identification of microorganisms, and 
to prevent misidentification of microorganisms, the MuxBCT test must be interpreted 
correctly. To do this, the operator is required to read the necessary wells in the correct 
order, which is dependent on the results of the classifier. Additionally, the use of 
MuxBCT requires an operator skilled in fluorescence microscopy and in operating 
molecular tests in order to provide an accurate reading. These tasks are outside what 
is commonly used by medical laboratory scientists (MLSs) in clinical microbiology 
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when analyzing positive BCs [14]. This is an important aspect to consider in 
comparison to the routine diagnostic methods [63].  
An example of the algorithm users must employ to correctly read and interpret the 
slide is shown in Figure 4. In the example, an initial reading of the classifier indicates 
Gram-positive bacteria, which requires the reading of well 8 as a negative control. If 
the negative control passes, then the user reads the wells 1, 2 and 3 for identification 
of Gram-positive bacteria. For polymicrobial BCs that for example contains both 
Gram-positive and Gram-negative bacteria, the user will be required to read eight 
wells. 
 
Figure 4. Example of a MuxBCT slide reading pattern followed when the classifier (well 5) 
indicates Gram-positive bacteria. In total, five wells must be read using fluorescence 
microscopy in the order given by the numbers and arrows to obtain a valid MuxBCT result in 
this example.   
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CHAPTER 4. THESIS OBJECTIVE 
As described in the background chapter, the use of tablets in clinical settings may 
facilitate complex workflows. Tablets may also be a valuable tool for the integration 
of advanced diagnostic tests with the LIS, which can allow for effective 
communication of test results. As a part of the MuxBCT project, this thesis explores 
if a tablet app can be used to facilitate the workflow of the MuxBCT test.  The thesis 
has the following objective: 
Investigate how to design and evaluate a tablet app that can facilitate the workflow 
of an advanced molecular sepsis diagnostic test, the MuxBCT, in a clinical 
microbiology laboratory. 
The thesis has the following four research aims in order to address the objective: 
1. Identify and understand necessary requirements for the MuxBCT app to 
support MLSs in the use of the MuxBCT test.  
2. Design a system architecture that is flexible to allow the MuxBCT app to 
exchange data with LISs while promoting security of data.  
3. Develop a prototype of the MuxBCT app based on the system requirements 
and the designed system architecture. 
4. Evaluate the ability of the app to facilitate the workflow of MLSs in their 
use of MuxBCT for BC analysis in a clinical microbiology laboratory.   
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CHAPTER 5. MUXBCT TABLET APP 
A MuxBCT app was designed during the PhD study to facilitate the workflow of the 
MuxBCT diagnostic test. To accomplish this, the following goals were set for the 
app: 
1. Provide guidance for MuxBCT test reading and result interpretation to 
reduce test complexity. 
2. Allow entry of test results directly on the tablet at the site of analysis.  
3. Support LIS communication in order to retrieve and display relevant sample 
information and to submit MuxBCT results from the tablet to the LIS. 
The MuxBCT app is designed to support mobility requirements of the user (i.e. a 
MLS), who conducts the MuxBCT diagnostic test. As the MuxBCT test requires the 
use of a fluorescence microscope, the slide reading will occur in a dark room. The 
MuxBCT tablet can be placed next to the microscope, and users can enter findings 
directly into the app. The app will then guide the users through the interpretation 
process in a stepwise manner. The use of the MuxBCT app should eliminate the need 
for paper procedure guides or paper forms for documentation of microorganism 
findings.  
Once a user has analyzed all relevant MuxBCT wells of a slide, the app presents the 
test results to the users. If the MLS accepts the results, the app transfers the MuxBCT 
results to the LIS. The MuxBCT tablet exchanges data with the LIS using a protected 
Wi-Fi connection. The LIS provides integration with the EHR and thereby makes 
MuxBCT results available for the attending physician, once the test result has been 
signed by a clinical microbiologist in the LIS.  
A wireless barcode scanner is available for the MLS to use. The scanner is connected 
to the MuxBCT app via Bluetooth, which allows for easy entry of barcode data into 
the app, e.g., BC accession number. The use of barcodes plays a large role in ensuring 
quality and efficiency in the routine analysis process of positive BCs [94]. An 
overview of the MuxBCT app is shown in Figure 5. An example of the MuxBCT 
app’s user interface is presented in Figure 6. 
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Figure 5. Overview of the MuxBCT tablet app, which is connected to a wireless barcode 
scanner and the LIS. The dashed lines indicate wireless transfer of data. The figure is adapted 
from Paper D. 
 
Figure 6. The MuxBCT app running on an Android tablet. In the example, a user has marked 
observations of green cocci cells during an examination of the classifier well.  
5.1. SYSTEM DESIGN 
This section describes the overall system design of the MuxBCT app, and the 
implementation, which was used to connect the MuxBCT app with the LIS (wwLab) 
of the Department of Clinical Microbiology, Aalborg University Hospital. 
An overall aim of the system design of the MuxBCT app was to ensure flexibility, to 
support easy integration with different LISs. Additionally, an aim of the system 
design was to promote data security. The system design consists of the following 
three main components: 1) a MuxBCT tablet app; 2) a MuxBCT server; 3) a MuxBCT 
database. An overview of the MuxBCT app system design is shown in Figure 7. 
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Figure 7. The overall MuxBCT system design. The dashed line indicates connectivity over a 
secure Wi-Fi connection. The figure is adapted from Paper C. 
The MuxBCT app was designed for 10-inch tablets with the Android operating 
system. The implementation of the MuxBCT app was done with Java using the 
Android SDK. The MuxBCT server was setup using Apache Tomcat 7.0, and the 
server software was developed with Java using the Spring framework. The MuxBCT 
database was implemented as a relational SQL Server 2012 database.  
Throughout the PhD study, an algorithm was designed and implemented into the 
tablet app for assisting users in reading the MuxBCT test slide in a stepwise manner. 
The algorithm provides instructions to users in order to do a structured interpretation 
of the MuxBCT slide in a stepwise manner, which simplifies the task of reading the 
MuxBCT test. The algorithm was continuously updated as the development of the 
MuxBCT test progressed to ensure that the algorithm would provide the correct test 
results. As the algorithm is integrated into the MuxBCT app, it was evaluated as a 
part of the MuxBCT app usability evaluation studies.  
The MuxBCT server was developed with a service-oriented architecture (SOA) in 
order to support efficient and flexible communication between the MuxBCT app and 
MuxBCT server and between the MuxBCT server and the LIS. The MuxBCT server 
offers several REST web services that are called from the MuxBCT app. Data 
between the MuxBCT app and server is transferred using the JSON data format. Data 
exchange between the MuxBCT server and LIS depends on what web services are 
offered by the LIS. In the implementation of this PhD study, the LIS offered SOAP 
web services, and data was transferred as XML. The SOA used in the system design 
allows multiple users to utilize the MuxBCT app to exchange data with the MuxBCT 
server simultaneously, thus multiple tablets with the MuxBCT app could be used in 
a clinical microbiology laboratory.  
Whenever patient or test information is required, the MuxBCT app requests the data 
as necessary through web services offered by the MuxBCT server. The MuxBCT 
server procures the necessary data through web services provided by the LIS and 
returns the data to the tablet app.  When a MuxBCT test result is ready, the MuxBCT 
app sends it to the MuxBCT server through a web service. In case of errors during 
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communication of data, an error message is returned to the MuxBCT app, which is 
then displayed to the user. For commonly encountered error cases (e.g. attempting to 
look-up a non-existing BC accession number), simple and clear error messages have 
been prepared and are displayed to the user to describe encountered issue.  
No data are saved locally on the tablet due to security concerns [95]. Instead, 
MuxBCT results are communicated to the MuxBCT server and saved in the MuxBCT 
database. The database is also used for logging user events and additional test data. 
All communication between the MuxBCT tablet app and the MuxBCT server takes 
place through a secure and closed hospital Wi-Fi network. Additionally, the network 
communication uses the TLS protocol for the encryption of data during transfer. 
The MuxBCT server primarily acts as a link that connects the MuxBCT app with the 
LIS. This brings the benefit that for integration with LISs of different vendors the 
tablet app does not need change. Instead, the MuxBCT server can be configured to 
match the requirements of the LIS. The MuxBCT server handles the majority of 
necessary computational work, i.e., mapping of data MuxBCT data to a format used 
by the LIS.  
All MuxBCT microorganism identification results are mapped to SNOMED CT IDs 
on the MuxBCT server. If a LIS supports SNOMED CT, the workload of system 
integration is significantly reduced. For the implementation at the Department of 
Clinical Microbiology at Aalborg University Hospital, a custom mapping was setup 
to exchange information with the LIS. The mapping from MuxBCT results in the 
form of SNOMED CT IDs to local laboratory codes was reviewed and validated by 
a clinical microbiologist from the Department of Clinical Microbiology at Aalborg 
University Hospital.  
Users are required to login on the MuxBCT app before the app can be used to guide 
use of the MuxBCT test. An authentication web service is called on the MuxBCT 
server, which in turn validates user credentials against a hospital user authentication 
web service. In the implementation during the PhD study, this meant that users could 
re-use their existing usernames and passwords that provided EHR access.  
5.2. DEVELOPMENT CYCLE 
The development of the MuxBCT app in the PhD study followed an iterative and 
user-centered approach, where the initial system requirements for the app was based 
on an analysis of the BC diagnostic workflow and of information about the MuxBCT 
test workflow. The focus of the development cycle was to support the workflow of 
the MuxBCT test. Therefore, the usability evaluation methods described in section 
2.2.2 were utilized in the iterations that provided feedback for app design 
improvements.  
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The duration of the development cycle from initial design until final prototype 
evaluation was approximately 2.5 years. Representative end users were involved in 
each evaluation of the app, which led to further optimization of the design of the app 
to support the MuxBCT test workflow. Neubeck et al. employed a similar 
participatory development approach in a recent study, which aimed to develop a 
mobile web app for use by patients [96].  
A challenge in the development of the MuxBCT app was that when the design of the 
MuxBCT test changed the design of the MuxBCT app had to be adapted to match the 
test. This occurred several times throughout the development cycle of the MuxBCT 
app. However, experiences gained through the evaluation of the MuxBCT app 
provided user input to the design of the MuxBCT test, which affected the 
development of the test. An illustration of the iterative development cycles of the 
MuxBCT test and the MuxBCT app is shown in Figure 8.  
 
Figure 8. The iterative development cycles of the MuxBCT test and the app are connected. 
MuxBCT in the figure refers to the MuxBCT test. Solid lines indicate processes that always 
occurs while dashed lines indicate a process that occasionally occurs.  
The design and development of the MuxBCT app underwent three iterations during 
this thesis. Different methods were used for the evaluation of the app as part of the 
development cycle, which depended on the fidelity of the app. All evaluations 
followed a participatory approach to increase the chance of identifying domain-
related workflow issues. An overview of iterations and the evaluation methods used 
for each iteration is shown in Figure 9.  
For the first iteration, the app’s functionality was modeled as a navigable user 
interface that was based on the initial requirements. The user interface was developed 
with the tool Justinmind Prototyper, which provided a high-fidelity representation of 
an app as an interactive website. This user interface prototype was evaluated using 
the usability inspection method participatory heuristic evaluation. Feedback from 
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usability experts and domain experts was used to improve app design in the second 
iteration.  
As part of the second iteration, the design was transformed to an initial MuxBCT app 
prototype. The prototype ran as an app on a tablet with the Android operating system.  
The second iteration was connected to the MuxBCT server, which allowed for 
evaluation of data transfer. The second iteration was evaluated in a clinical simulation 
study, where end users utilized the MuxBCT app to guide a simulated diagnostic test 
workflow of the MuxBCT test in a clinical microbiology laboratory. This provided 
valuable data on the feasibility of using an app in a clinical microbiology laboratory. 
Feedback from this step was used to guide the third iteration of the development cycle 
of the MuxBCT app. 
The third iteration was the final design and implementation of the MuxBCT app, 
which was connected to a LIS through a MuxBCT server. This iteration was 
evaluated through a prospective evaluation study, where the MuxBCT app was used 
to support MLSs in the use of the MuxBCT test for pathogen identification from 
positive BCs.   
 
Figure 9. Each iteration in the development of the MuxBCT app was evaluated in order to 
improve the design and development for the next iteration. The figure does not illustrate design 
changes to the MuxBCT app, which are due to changes in the design of the MuxBCT test.  
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CHAPTER 6. STUDY OVERVIEW 
This chapter provides an overview of the four studies that were conducted as part of 
this PhD thesis to answer the research aims. The studies followed the order as they 
are numbered below.   
6.1. STUDY 1 – PAPER A 
Study 1 was an observational study of the workflow during routine diagnostics of 
positive BCs in a clinical microbiology laboratory. The study aimed to provide a 
basic understanding of requirements for the MuxBCT app required to support BC 
workflow, thus addressing the first research aim of the thesis. Five MLSs with a 
varying degree of experience in the analysis of BCs were observed over a three day 
period in their work with analysis of positive BC. The observations were conducted 
for a total time of 13 hours and 30 minutes, which included both mornings and 
afternoons. The observations followed a semi-structured guide that focused on the 
analysis of blood cultures along with how test results were communicated. During 
the observations, notes were made of each activity and its location and duration. The 
use of any CIS was also noted, along with how it was used. The observational results 
were supported by two interviews to clarify observations. The interviews followed a 
semi-structured approach. The notes of the observations and interviews were coded 
into main categories and then analyzed in detail.  
The qualitative findings of the study provided an understanding of the workflow of 
BC analysis for the clinical microbiology laboratory in which the study took place. 
Furthermore, a set of system requirements that should be supported in the design of 
the MuxBCT app was generated from an analysis of the observations. The MuxBCT 
should be able to support two-way communication with the LIS to receive clinical 
data related to the analysis while being able to transfer test results. Barcodes should 
be supported, as they are used extensively in the BC workflow. The app should 
provide access to a browser for looking up analysis related guidelines.  The app 
should support communication of results from the MLTs to the clinical 
microbiologists.  
The implementation of new CIS is dependent on users being willing to adapt their 
workflows to fit the new system. By guiding further development of the MuxBCT 
app based on the findings of this study fewer changes to workflows will be required, 
which decreased the risk of users not being willing to use the system. A limitation of 
the study was the observations of the study was only conducted in one clinical 
microbiology laboratory, and workflows may differ in other laboratories. However, 
the study included five participants with a varying degree of experience in BC 
analysis, which provided a better understanding of the BC analysis workflow. The 
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results of the study were used as a basis for the design of the MuxBCT app in iteration 
1 of the development cycle. The findings of this study are described in Paper A and 
were presented at the MedInfo 2013 conference in Copenhagen, Denmark.  
6.2. STUDY 2 – PAPER B 
Study 2 partly addressed the third research aim of the thesis by transforming the 
system requirements into a prototype of the MuxBCT apps user interface, which was 
then evaluated to provide feedback for further design optimization. The study did not 
consider the architecture of the app but focused on the overall functionality. The 
prototype demonstrated the functionality of the app by having a user interface that 
fully modeled the app. The prototype of the user interface was designed and evaluated 
at iteration 1 of the development cycle. The prototype of was deployed on a 10-inch 
Android tablet to provide a realistic representation of the final MuxBCT app for the 
evaluation. The focus of the evaluation was to identify potential usability issues that 
could negatively affect the workflow. The chosen evaluation method was a 
participatory heuristic evaluation that involved the use of domain experts in order to 
identify potential issues related to the workflow support of the app prototype. 
Workflow issues closely related to the domain (i.e. clinical microbiology) would be 
difficult to identify by usability experts due to a lack of domain understanding.  
The prototype was evaluated by two evaluator groups that consisted of four usability 
experts and four work-domain experts, respectively. The domain experts were 
recruited from MLSs at a clinical microbiology laboratory, who all had experience in 
BC analysis and were representative for the MuxBCT app’s end users. The work-
domain experts were briefly trained in the heuristic evaluation method. None of the 
study participants had any previous knowledge of the MuxBCT app or the MuxBCT 
test. The participants were introduced to the MuxBCT app and the purpose of the 
study through both a written and verbal description. The study participants evaluated 
the app individually by completing a series of tasks asked by a study leader. When a 
heuristic violation was identified, it was assigned a group and a severity rating on a 
scale from 0-4 (no problem to usability catastrophe). After the study, the results from 
the participant were pooled, and duplicate heuristic violations were merged. 
The study resulted in the identification of 86 unique heuristic violations. 17 of the 
violations were identified only by the domain experts. The average violation was 
assigned a severity score of 2.05, and five violations were given the score of 4 
corresponding to catastrophe. The study results revealed usability issues related to 
both product and domain. The identified issues were used to guide the further design 
of the MuxBCT app. A limitation of the study was that the use of additional usability 
experts instead of domain experts could potentially have revealed the same work-
related heuristic violations. However, the results of the study indicate that the use of 
MLSs as domain experts was valuable as they identified 17 violations not found by 
the usability experts. The domain experts provided valuable insights by identifying 
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heuristic violations related to error prevention, quality of work, and privacy. These 
categories would not have been covered in the traditional heuristic evaluation, and 
would likely not have been covered adequately if only usability experts had 
participated in the study. The study results indicate that training work-domain experts 
for participatory heuristic evaluation of systems that aim to support complex clinical 
workflows can be valuable. The findings of the study are described in Paper B, which 
was presented at the MIE 2014 conference in Istanbul, Turkey. 
6.3. STUDY 3 – PAPER C 
Study 3 was designed to address the second and third research aims of this thesis. 
The system architecture of MuxBCT app was designed in iteration 2 of the 
development cycle. Based on this, the functional prototypes of the MuxBCT app and 
the MuxBCT server were developed. Study 3 was a clinical simulation study that 
brought the prototype of the MuxBCT app into a clinical microbiology laboratory in 
near-live simulation settings, to evaluate if it could facilitate the use of the MuxBCT 
test. In the study, the prototype MuxBCT app was not connected to the LIS but 
instead returned simulated realistic data from the MuxBCT server. A prototype of the 
MuxBCT test was not available at this point, so two different QuickFISH tests, which 
are similar in function to MuxBCT but only covers three microorganisms each, were 
used to simulate the MuxBCT test. Although the MuxBCT test was not available, this 
solution still allowed for testing the concept of the slide interpretation algorithm of 
the MuxBCT app, and to evaluate if the app could guide users to obtain accurate 
microorganism identification results. 
The study provided realistic settings to obtain results, which would closely match 
results obtained by an actual deployment of the MuxBCT app. Four MLSs 
participated in the study, and none of the participants had any prior experience with 
the MuxBCT app. The participants were trained by the test leader in the use of the 
MuxBCT app for about 10 minutes. In the training, each participant carried out a set 
of predefined tasks with the app. During the study, the participants did not receive 
any assistance from the test leader. The test leader acted as an observer, as each 
participant individually examined two mocked blood cultures containing a 
microorganism each. Audio was recorded with a Dictaphone during the study. 
Additionally, all tablet touch interactions with the MuxBCT app was recorded 
directly on the tablet. Users were debriefed after the study based on observations by 
the test leader. Observations were coded in categories by type of event and then 
interpreted to identify potential usability issues.  
The study participants identified all eight microorganisms correctly from the mocked 
BCs, and the results were communicated successfully from the MuxBCT app to the 
MuxBCT server. The average analysis time of a BC sample was 10.2 min excluding 
time for preparation of the sample. During the debriefing interviews, three of four 
participants indicated that they preferred the use of the MuxBCT app compared to 
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paper as for routine diagnostics. The main finding of the study was that the 
participants (i.e. MLSs) were successfully able to use the MuxBCT app to facilitate 
the use of the simulated MuxBCT test even though they were only provided with a 
brief training session. Furthermore, the study did not identify any major usability 
issues, but minor usability issues related to the user interface were identified. The 
study also evaluated the system design consideration, e.g. system connectivity and 
data security, which did not cause any issues for the participants in the study.  
It was a limitation of the study that the MuxBCT test had to be simulated, as a 
functional prototype was not yet ready as this detracted from the realism of the study. 
However, by conducting the simulation study in a clinical microbiology laboratory, 
the study could be carried out under very realistic conditions despite the need for the 
simulated MuxBCT test. This meant that the results would likely be representative of 
the normal use of the MuxBCT app for supporting the use of the MuxBCT test. These 
usability findings of the study were used to guide iteration 3 of the development 
cycle. The study findings indicated that the implemented system architecture was 
feasible, as the participants had access to the necessary clinical information through 
the app. Furthermore, the study also indicated that it was feasible to use of the 
MuxBCT tablet app to guide MLSs in the use of the MuxBCT test. The design of the 
system architecture along with the findings of the clinical simulation study are 
described in Paper C. 
6.4. STUDY 4 – PAPER D & PAPER E 
Study 4 was an evaluation study where the MuxBCT app was evaluated together with 
a functional prototype of the MuxBCT test in a clinical microbiology laboratory. This 
addressed the fourth research aim of the thesis. The study evaluated the accuracy 
MuxBCT results, timeliness of MuxBCT results, and the usability of the MuxBCT 
app. The study was conducted as a non-interventional study that ran in parallel with 
the routine analysis of positive BCs. Four MLSs participated in the study. The 
participants had no previous knowledge of the MuxBCT test or app, and they had a 
varying degree of experience with the analysis of BCs. In preparation for the study, 
the MuxBCT app was connected with the LIS of the laboratory so that clinical data 
could be retrieved from the LIS and MuxBCT results could be sent to the LIS.  
MuxBCT results were saved in the LIS separately from normal results. Participants 
were trained by carrying out a set of predefined tasks as a part of a 6-hour training 
session that included training in both the use of the MuxBCT test and the MuxBCT 
app. 
The MuxBCT test was used for analysis of 137 positive BCs over five weeks in a 
clinical microbiology laboratory. Data from 124 BCs was available for further 
analysis after exclusion of samples that had not been analyzed simultaneously in the 
routine diagnostic process and with the MuxBCT test. The MuxBCT app guided the 
analysis of BCs with MuxBCT test, and test results were entered directly into the 
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tablet app and then communicated to the LIS. The accuracy of MuxBCT results was 
92.7% when compared with routine diagnostic findings. In debriefing interviews and 
from study notes, the participants indicated that the discordant test results were 
primarily related to the prototype MuxBCT test. MuxBCT results were available in 
the LIS with a median time of 74.2 min. This was close to the time for availability of 
preliminary results (i.e. Gram stain reaction) in the LIS obtained from the routine 
diagnostic methods with a median time of 54.4 min. The median time that the 
MuxBCT app was actively used during analysis of a MuxBCT test was 2.8 min. The 
usability of the MuxBCT app was evaluated through SUS questionnaires and 
debriefing interviews at the end of the study. The tablet app was given a SUS score 
of 93.4 at the onset of the study and a score 94.4 at the end of the study. The SUS 
scores indicated a system with few usability issues. In the debriefing interview, users 
further indicated that the MuxBCT app had successfully facilitated the workflow of 
the MuxBCT test and that they were satisfied with the app.  
While the MuxBCT results in this study are from one clinical microbiology 
laboratory, similar results would likely have been obtained from other laboratories, 
as the MuxBCT workflow would have been similar. However, the routine diagnostic 
process would likely have produced different results depending on the routine 
methods used for BC analysis at the laboratory.  The fact that the MuxBCT test was 
used as a part of a normal workday over a five-week period means that the results of 
the study can be representative of use of the MuxBCT test and MuxBCT app as a part 
of a routine diagnostic workflow. The performance and usability of the MuxBCT 
tablet app are described in Paper D. The concordance of MuxBCT results and the 
timeliness of MuxBCT results when supported by the MuxBCT tablet app is 
described in Paper E. 
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CHAPTER 7. PAPERS 
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CHAPTER 8. DISCUSSION 
The use of informatics tools in clinical microbiology is a way to accomplish more 
with fewer resources [8]. As such, there is an interest in the use of tablets for 
supporting the workflows of advanced molecular diagnostic tests for rapid 
identification of microorganisms from BCs [70]. The use of molecular diagnostic 
tests for rapid identification of microorganisms for use in clinical microbiology has 
increased in recent years, and the tests have the potential to improve the outcome of 
sepsis patients. However, the molecular diagnostic tests grow more complex to 
operate in comparison to routine diagnostic methods. Tablets with specialized apps 
can potentially support the implementation of the advanced diagnostic tests by 
providing support of the workflow during analysis, and by efficiently assisting 
communication of test results.  
This thesis was part of a research project that aimed to develop the MuxBCT test, 
which is a rapid molecular diagnostic test for identification of microorganisms in 
positive BCs. The objective of this thesis was to investigate how to design and 
evaluate a specialized tablet app for supporting the workflow of the MuxBCT test in 
a clinical microbiology laboratory.  
8.1. METHODOLOGY 
In this thesis, a MuxBCT tablet app was designed through a user-centered approach, 
where an iterative development cycle was used. For each iteration of the development 
cycle, the functionalities of the MuxBCT app were improved. Each iteration of the 
app design was implemented as a prototype and evaluated with a participatory 
approach. An example of this is study 2 where a participatory heuristic evaluation 
was conducted with participation of representative end users that were able to identify 
workflow related usability issues [97]. This allowed for an early optimization of the 
design of the MuxBCT app, where usability flaws were corrected before the 
MuxBCT app was evaluated in situ for supporting the MuxBCT test.  
A challenge in developing the MuxBCT app was that it was being developed 
concurrently with the MuxBCT test, which it was being designed to support. The 
functionalities of the MuxBCT test evolved during this thesis. Each change of 
functionality of the test had to be mirrored in the app to support the workflow of the 
test to obtain accurate test results. The incremental development cycle was well suited 
for this, as each change in functionality was able to be evaluated in each iteration of 
the MuxBCT app.  
In the studies of this thesis, the initial requirements for the MuxBCT app were 
collected through an observational study of the existing workflow of BC analysis. In 
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general, the evaluation methods selected for evaluation of CISs should be chosen 
depending on the goals of the study [98]. This aspect was considered for the 
evaluation studies conducted as a part of this PhD thesis, as each study method 
corresponded to the fidelity of the MuxBCT app at the time of the evaluation. This 
meant that for each iteration, increasingly complex evaluation methods were selected 
to provide valid results. By using evaluation methods that closely matched real use 
of the MuxBCT app, potential usability issues related to workflow support could be 
identified before the MuxBCT app was evaluated together with the MuxBCT test in 
study 4.  
In the evaluation study of the MuxBCT app, the app was used to support a functional 
prototype of the MuxBCT test for identification of microorganisms from positive 
BCs. The study was conducted as part of a normal workday over a  five week period, 
which allowed the final evaluation of the MuxBCT app to be a strong representation 
of an implementation into normal diagnostic routines. As the MuxBCT test was used 
in parallel with the routine diagnostic methods, this provided a method to directly 
estimate the accuracy of the MuxBCT test when supported by the MuxBCT app, and 
the timeliness of the MuxBCT results in comparison to routine diagnostic methods.  
8.2. MAIN FINDINGS 
To meet clinical needs, advanced molecular diagnostic tests for use in clinical 
microbiology should provide rapidly available results that are accurate and reliable 
[40]. A functional prototype of the MuxBCT test was supported by a final iteration 
of the MuxBCT tablet app in study 4 for the analysis of positive BCs. When supported 
by the MuxBCT app, microorganism identification results with an accuracy of 92.7% 
were obtained from the MuxBCT test from the analysis of 124 BCs. The MuxBCT 
results were available in the LIS after a median processing time of 74.2 min, which 
was close to the time of availability of preliminary results (i.e. Gram stain results) in 
the LIS at a median time of 54.4 min. These are promising results, as they could allow 
accurate microorganisms identification results obtained by the use MuxBCT to be 
reported alongside traditional preliminary microbiology findings. The final 
microorganism identification results obtained by traditional methods were available 
in the LIS with a median time of 24.9 hours. Thus, for a range of microorganisms, 
there is a potential to save close to a day in time to obtain final identification results 
by using the MuxBCT test.  
In study 4, the usability of the MuxBCT app was evaluated in a mixed approach by 
examining the accuracy of test results, notes from study participants, and from 
participant debriefing interviews. Few usability issues were identified in the 
MuxBCT app, and the discordant microorganism identification results was reported 
by participants to be primarily due to weak fluorescent signals in some wells of the 
functional prototype of the MuxBCT test. These primarily positive study results were 
obtained even though users had received limited training in the use of the MuxBCT 
CHAPTER 8. DISCUSSION 
 49 
test and the MuxBCT app. For 11 of the analyzed BCs there was an extra level of 
complexity, as these BCs were polymicrobial. However, this did not cause any issues 
during analysis as the app guide the uses in a stepwise manner, despite these samples 
required reading of additional wells of the MuxBCT test to obtain test results.  
A strength of the MuxBCT test is its ability to rapidly identify a wide array of 
microorganisms from positive BCs in a single test. This can lead to an early 
optimization of a patient’s initial wide-spectrum antimicrobial therapy to a targeted 
small-spectrum therapy. Based on results from studies on the PNA-FISH and 
QuickFISH tests, this can lead to an improved patient outcome and reduced cost of 
treatment when combined with an effective communication of the results 
[42,49,50,99]. However, to obtain these benefits, the diagnostic tests must be 
effectively implemented into clinical workflows to quickly communicate the test 
results to the attending physician of the sepsis patient, and that the results acted upon 
if necessary [52]. The MuxBCT test alone affects the TAT of BC test results by 
reducing the time for analysis of BCs. However, when combined with the MuxBCT 
app, the TAT is likely further reduced by making the results directly available in the 
LIS once they have been entered in the tablet app, which supports a quick 
communication of the test results.   
BCs are often processed in batches in a stepwise manner in clinical microbiology 
laboratories due to practical considerations [12]. The analysis of BC in batches 
promotes a more efficient workflow during the analysis. This was also seen in the 
results of the evaluation study of the combined use of the MuxBCT app and MuxBCT 
test, where the average batch had a size of 3.1 BCs. If results of all tests are initially 
captured on paper forms and entered into the LIS, then further communication of test 
results is not possible until the analysis of all samples has been completed. This 
reduces the potential benefits gained by the use of rapid molecular diagnostic tests as 
it increases the TAT. In cases like this, the MuxBCT app offers an additional 
optimization of the test TAT by making each sample results directly available in the 
LIS, thus allowing further processing while the rest of the batch is still undergoing 
analysis.  
By entering results directly on the tablet, a need for double documentation of test 
results is eliminated, which can help eliminate the risk of errors during manual entry  
of results at a workstation [66]. It has been shown that this is a source a potential 
source of errors in clinical microbiology laboratories, and that system interfaces that 
reduces the need for manual entry reduces both data entry errors and hands-on time 
[8]. The slide interpretation algorithm for the MuxBCT test that is built into the 
MuxBCT app ensures that all tests are analyzed in a consistent manner. Additionally, 
the recording of all MuxBCT test results is standardized. The algorithm promotes 
quality of MuxBCT test results by enforcing that users initially interpret the negative 
test well of the MuxBCT test. If the negative test fails, the app ensures that no other 
test results from that MuxBCT test can be communicated to the LIS. These factors 
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lower the risk of errors in test results when a tablet with the MuxBCT app is used to 
support the MuxBCT test.  
The introduction of the MuxBCT app into the workflow of BC analysis causes a 
disruption to normal working routines. The workflow during test analysis becomes 
dictated by the interpretation algorithm of the MuxBCT app.  Furthermore, the 
MuxBCT app only provides a limited but specially tailored access to clinical 
information. Despite these changes to the freedom of BC analysis workflow, a 
general satisfaction of using the tablet app was expressed in debriefing interviews of 
participants. It is important that the MLSs feel that the MuxBCT app supports their 
workflow with the MuxBCT test for the MuxBCT app to be accepted and 
successfully implemented [82].   
The architecture of the MuxBCT app was proven to be a feasible approach as it 
allowed the MuxBCT app to exchange data with the LIS in use at the Department of 
Clinical Microbiology at Aalborg University Hospital. The SOA used in the system 
design of the MuxBCT app is a generally accepted software architecture in healthcare 
used for promoting system interoperability and flexibility [100].  
The use of a tablet that offers access to sensitive clinical information caused 
challenges in the design of the system architecture, as it sets a need for the design of 
security features. The challenge of information security faced with the MuxBCT app 
is a general challenge in the design of CISs for smartphones and tablets [4,95,101]. 
To prevent potential misuse if the tablet was stolen or lost, no data from the MuxBCT 
app was stored locally on the tablet. Furthermore, all data was encrypted during 
communication between the tablet and the LIS. Users were required to log in, before 
they could access the functionality of the MuxBCT app, but they were not otherwise 
restricted by the security features designed for the MuxBCT app. No users reported 
any issues related to the security features during the debriefing interviews after the 
evaluation study. The model for security features used in the architecture of the 
MuxBCT app could be reused in the design of other apps for smartphones and tablets 
that is designed for use in clinical settings. Landman et al. has presented a similar 
approach to security features for a smartphone app designed for capturing and 
communicating clinical images [101].  
The results of the evaluation study of the MuxBCT indicates that the use of 
specialized tablet apps such as the MuxBCT app may be valuable for use in clinical 
laboratories as well as in other clinical settings. The results add to the existing 
published studies that suggests that tablets may be able to promote more efficient 
workflows in clinical settings while supporting work of high quality [4,76].  
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8.3. LIMITATIONS  
The evaluation studies conducted through this thesis has focused on the combined 
microorganism identification results when the MuxBCT app was used to support the 
MuxBCT test. This provides a limitation in estimating the effect contributed by the 
MuxBCT tablet app, as there are no standalone results of the MuxBCT test that can 
be used for a comparative analysis.  
A limitation of the studies conducted in this thesis is the inclusion of few participants 
in each study. However, this is not an uncommon approach in usability evaluations 
where few participants can provide a cover of a large amount of potential usability 
issues [102]. For study 4, each participant used the MuxBCT app and MuxBCT test 
for the analysis for 22 or more positive BCs, which meant that each participant had a 
thorough experience with the app and the test. To increase the generalizability of the 
study results, the participants of the studies were recruited with varied backgrounds 
in regards to their age and their experience with analysis of BCs.  
Results obtained from evaluation studies of CISs can only be generalized to similar 
environments [98]. This aspect affects the generalizability of the results from the 
studies of this thesis, as the same clinical microbiology laboratory in Denmark was 
the main partner for the design, development, and evaluation of the MuxBCT app. 
This means that there is a risk of the developed MuxBCT app not being as flexible a 
system as intended. However, while gathering requirements for the MuxBCT app, 
workflow of BC analysis was observed in two laboratories in the USA to provide an 
improved understanding of the BC analysis workflow [94]. While there were some 
workflow differences observed, the main differences were related to communication 
of results from the laboratory to the attending physician [63,94]. As the result 
communication was not in focus during the final evaluation of the MuxBCT 
prototype, the obtained results are likely representable for many clinical 
microbiology laboratories.  
8.4. CONCLUSION 
A MuxBCT tablet app was designed and developed in this thesis, and the app was 
evaluated under realistic conditions. The app was designed in an iterative manner 
with a user-centered approach. The evaluation study demonstrated that the MuxBCT 
app was successfully able to facilitate the users during the MuxBCT test workflow, 
as the users could successfully interpret test results when guided by the MuxBCT 
app. Furthermore, the results were communicated directly from the tablet app to the 
LIS. In conclusion, the use of the MuxBCT app supported the use of the MuxBCT 
test, which led to a timely and accurate microorganism identification results from 
positive BCs.  
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This thesis has provided an initial investigation into the use of a specialized tablet 
app for supporting the workflow of an advanced diagnostic test in a clinical 
laboratory. The results of the studies from this thesis may indicate that workflow 
optimizations can be gained by using tablets for supporting diagnostic tests in clinical 
laboratories. A user-centered and participatory approach to design and development 
of tablets apps for use in clinical settings can allow for successful support of complex 
clinical workflows.  
8.5. FUTURE PERSPECTIVES 
The effect of the MuxBCT app on result accuracy and time to result availability 
would be relevant to investigate in a future study. This could be examined by 
conducting an evaluation study with a similar design as the evaluation study of this 
thesis, but without the use of the MuxBCT app to guide the test interpretation. 
Instead, study participants should rely on a standard test procedure guide for the 
MuxBCT test during the interpretation of the MuxBCT test. Additionally, results 
should be documented as in the routine diagnostic process of positive BCs, i.e., 
initially on paper forms that are later entered into the LIS at a workstation. It would 
also be relevant to conduct future evaluation studies of the MuxBCT app and the 
MuxBCT test in other clinical microbiology laboratories to further validate the results 
of this thesis.  
The MuxBCT tablet has a potential to reduce the TAT of test results if it is expanded 
with capabilities to provide automated and direct notification when test results are 
available for further processing. Depending on the laboratory, one potential use 
would be to notify medical microbiologists or AST that the MuxBCT test results are 
ready for communication to the patient's treating physician. In other laboratories, it 
could be implemented as a message sent directly to an attending physician of a sepsis 
patient.   
With the ongoing development of advanced tests in clinical microbiology, there will 
be an increased need to ensure that these devices can communicate with LISs to 
reduce workflow complexity and minimize workload [8]. For diagnostic tests that are 
not integrated into fully automated instruments, the use of specialized tablets apps to 
integrate these systems with the LIS may become an important strategy for ensuring 
that the tests results are quickly made available where needed.
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